IP Library Granted Patent US 8,034,015
Granted Patent B2
US 8,034,015 · App. 12/111,109 · Granted Oct 11, 2011

Anti-clotting apparatus and methods for fluid handling system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,034,015
App. No.
12/111,109
Granted
Oct 11, 2011
Kind
B2
Abstract

A method for maintaining clear passageways in an extracorporeal blood flow system. The method comprises intermittently providing one or more anti-clotting agents to a passageway of the extracorporeal blood flow system. Also disclosed is an extracorporeal blood flow system. The system comprises a passageway, and a device operatively connected to provide one or more anti-clotting agents to a least a portion of said passageway.

Claims (35)

1. A system for analysis of bodily fluids, the system comprising:

a first fluid passageway in fluid communication with a fluid source;

a second fluid passageway in fluid communication with the first passageway;

a pump configured to draw a fluid sample into the first fluid passageway from the fluid source;

a valve operatively connected to at least one of the first or second fluid passageways, the valve being configured to separate an analysis portion from the fluid sample;

an analyzer operatively connected to the second passageway, the analyzer being configured to determine the concentration of at least one analyte in the analysis portion of the fluid sample;

an anti-clotting device operatively connected to provide one or more anti-clotting agents to only the analysis portion; and

a waste reservoir in fluid communication with the second passageway, the waste reservoir configured to collect the analysis portion of the fluid sample so that it is not returned to the fluid source.

2. The system of claim 1 , further comprising a controller configured to operate the fluid flow system such that at least a portion of the fluid sample is returned to the fluid source.

3. The system of claim 1 , wherein the controller operates the pump to return a portion of the fluid sample to the fluid source.

4. The system of claim 3 , wherein the controller is configured to operate the valve to prevent the analysis portion of the fluid sample from returning to the fluid source.

5. The system of claim 1 , wherein one of said one or more anti-clotting agents comprises a substance infusible into the fluid sample.

6. The system of claim 5 , wherein the substance infusible into the fluid sample comprises a detergent.

7. The system of claim 6 , wherein said detergent comprises a protease enzyme.

8. The system of claim 5 , wherein said anti-clotting device is configured to provide said infusible substance to the fluid sample when it is within at least a portion of said second passageway.

9. The system of claim 5 , wherein the system is further configured to prevent the substance, or the analysis portion infused therewith, from entering the fluid source.

10. The system of claim 1 , wherein said fluid flow system comprises a point-of-care analyte monitoring system.

11. The system of claim 10 , wherein said point-of-care analyte monitoring system comprises an optical detection device, wherein said second passageway comprises an optical measurement cell, and wherein said one or more anti-clotting agents is provided at or near said optical measurement cell.

12. The system of claim 11 , wherein said point-of-care analyte monitoring system comprises a spectroscopic analyzer.

13. The system of claim 12 , wherein said spectroscopic analyzer comprises an infrared spectrometer configured to determine glucose concentration.

14. The system of claim 1 , wherein one of said one or more anti-clotting agents comprises ultrasonic energy.

15. The system of claim 1 , wherein said anti-clotting device comprises an ultrasound generator positionable to contact said second passageway.

16. The system of claim 15 , wherein said ultrasound generator generates from approximately 2 Watts to approximately 200 Watts of ultrasonic energy.

17. The system of claim 15 , wherein said ultrasound generator generates ultrasound having a frequency of approximately 40 kHz.

18. A system for analysis of bodily fluids, the system comprising:

a first fluid passageway in fluid communication with a fluid source and configured to receive a fluid sample from the fluid source;

a valve operatively connected to the first fluid passageway, the valve being configured to separate an analysis portion from the fluid sample;

an analyzer configured to interact with the analysis portion to determine at least one analyte in the analysis portion of the fluid sample;

an anti-clotting device configured to provide one or more anti-clotting agents to only the analysis portion; and

a waste reservoir configured to collect the analysis portion of the fluid sample so that it is not returned to the fluid source.

19. The system of claim 18 , further comprising a second fluid passageway in fluid communication with the first passageway, the second fluid passageway configured to receive the analysis portion.

20. The system of claim 19 , wherein the anti-clotting device is operatively connected to the second fluid passageway.

21. The system of claim 19 , wherein the anti-clotting device is fluidly coupled to the second fluid passageway.

22. The system of claim 18 , wherein the analyzer is configured to determine the concentration of the at least one analyte in the analysis portion of the fluid sample.

23. The system of claim 18 , further comprising a pump configured to draw a fluid sample into the first fluid passageway from the fluid source.

Assignments (5)
AMENDED AND RESTATED IP SECURITY AGREEMENT Recorded Feb 28, 2018
From: OPTISCAN BIOMEDICAL CORPORATION
To: EAST WEST BANK
Reel/Frame 045469/0948 →
RELEASE OF SECURITY INTEREST Recorded Jan 11, 2017
From: HERCULES TECHNOLOGY II, L.P.
To: OPTISCAN BIOMEDICAL CORPORATION
Reel/Frame 041344/0534 →
ASSIGNMENT AND RELEASE OF SECURITY INTEREST Recorded Dec 18, 2013
From: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
To: OPTISCAN BIOMEDICAL CORPORATION
Reel/Frame 031847/0600 →
SECURITY AGREEMENT Recorded Dec 13, 2013
From: OPTISCAN BIOMEDICAL CORPORATION
To: EAST WEST BANK
Reel/Frame 031815/0377 →
SECURITY AGREEMENT Recorded May 23, 2008
From: OPTISCAN BIOMEDICAL CORPORATION
To: HERCULES TECHNOLOGY II, L.P.
Reel/Frame 020995/0202 →